Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Active not recruiting 3Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

B-cell Malignancies 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27venetoclax 25Specimen Handling 25Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Docetaxel 22Biopsy 22Radiotherapy 21Ipilimumab 21Bevacizumab 21Azacitidine 21Radiosurgery 18Dexamethasone 18durvalumab 17Fluorouracil 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14tislelizumab 13Leucovorin 13Cytarabine 13olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × idelalisib × 1 year × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡